X

Trial Profile

Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 21 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Ulixertinib (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions

Most Recent Events

08 Feb 2023 Results assessing safety and efficacy of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma, published in the Oncologist
21 May 2020 Status changed from active, no longer recruiting to discontinued.
23 Sep 2019 Planned End Date changed from 31 May 2022 to 31 Mar 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com